The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Huwel’s diagnostic solutions leverage open RT-PCR system
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The first of four planned modules at the new plant is expected to come online by summer 2026
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
